← Leaderboards
Darren John Moore
Van Andel Research Institute
$10,901,167
Attributed
$11,951,617
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,951,617 · 10
By mechanism
R01$9,233,031 · 5
R21$1,442,206 · 3
R56$840,282 · 1
R33$436,098 · 1
Top collaborators
- Jeffrey H Kordower1 shared
- Michael K Lee1 shared
- Keith Alan Vossel1 shared
- Daniel W Wesson1 shared
Most similar at Van Andel Research Institute
Same institution · by research overlap
- Patrik Brundin$3,355,919
- Hong-Yuan Chu$3,066,117
Others in their field
Top investigators on “Nerve Degeneration”
- Paul S. Aisen · Cognition Therapeutics, Inc.$113,855,136
- Reisa A. Sperling · Banner Health$83,196,776
- Randall J Bateman · Washington University$83,099,227
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$76,236,227
- Jose A Luchsinger · Columbia University Health Sciences$75,117,371
- Keith A. Johnson · Banner Health$70,466,464
Research focus
Nerve DegenerationNeuronsParkinson DiseaseSubstantia Nigra StructureDopaminergic NeuronGenesMutantBrainProteinsLinkMutationMolecularMediatingVariantGene TransferFunctional DisorderLrrk2 GeneAnimal ModelMovement DisordersRattusComplexInnovationInsightRodent Model
Grant awards (28)
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease$427,500
R01 · FY2025 · NS · contact PI
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease$460,750
R01 · FY2024 · NS · contact PI
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models$433,105
R01 · FY2024 · NS · contact PI
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease$475,000
R01 · FY2023 · NS · contact PI
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models$446,500
R01 · FY2023 · NS · contact PI
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease$475,000
R01 · FY2022 · NS · contact PI
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models$446,500
R01 · FY2022 · NS · contact PI
Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease$436,098
R33 · FY2022 · NS · contact PI
Alpha-Synuclein Induced Network Hyperexcitability in Lewy Body Dementias$840,282
R56 · FY2021 · AG
Linking Synucleinopathy and Dysfunction of Olfactory Pathways$544,426
R01 · FY2021 · DC · contact PI
Role of T cells in alpha-synuclein pathology$525,081
R21 · FY2021 · NS · contact PI
LRRK2 Enzymatic Mechanisms of Neurodegeneration in Parkinson's Disease$475,000
R01 · FY2021 · NS · contact PI
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models$446,500
R01 · FY2021 · NS · contact PI
Mechanisms of VPS35-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2021 · NS · contact PI
Exploring mechanisms of Parkinson's disease-linked D620N VPS35 in rat models$446,500
R01 · FY2020 · NS · contact PI
Mechanisms of VPS35-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2020 · NS · contact PI
Novel Mechanisms of LRRK2-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2019 · NS · contact PI
Mechanisms of VPS35-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2019 · NS · contact PI
Developing novel treatments for Parkinson's disease by targeting molecular pathways that have been shown to modulate aging$237,500
R21 · FY2019 · AG · contact PI
Mechanisms of VPS35-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2018 · NS · contact PI
Novel Mechanisms of LRRK2-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2018 · NS · contact PI
Developing novel treatments for Parkinson's disease by targeting molecular pathways that have been shown to modulate aging$285,000
R21 · FY2018 · AG · contact PI
Mechanisms of VPS35-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2017 · NS · contact PI
Novel Mechanisms of LRRK2-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2017 · NS · contact PI
Novel Mechanisms of LRRK2-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2016 · NS · contact PI
Novel Mechanisms of LRRK2-Dependent Neurodegeneration in Parkinson's Disease$415,625
R01 · FY2015 · NS · contact PI
Alpha-Synuclein Conditional Knock-in Mice as Novel Models of Parkinson's Disease$215,250
R21 · FY2008 · NS · contact PI
Alpha-Synuclein Conditional Knock-in Mice as Novel Models of Parkinson's Disease$179,375
R21 · FY2007 · NS · contact PI